Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2005
09/29/2005US20050214813 Amyloid-beta protein aggregation-regulating factors
09/29/2005US20050214800 Human zven proteins
09/29/2005US20050214798 Bridging integrator-2 (Bin2) nucleic acid molecules and proteins and uses therefor
09/29/2005US20050214795 Polypeptide for use as diagnostic indicator of cell proliferative disorders; immunotherapeutics; antitumor agents
09/29/2005US20050214793 Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter protein ABC1
09/29/2005US20050214781 Ovarian specific nucleic acid (OSNA) for use in diagnosis, prevention and treatment of cell proliferative disorders; immunotherapy; genetic vaccines
09/29/2005US20050214780 Using polymorphism in potassium channel interacting protein (KChIP1) as diagnostic indicator for pancreatic disorders
09/29/2005US20050214773 Recombinant UDP-N-acetylmuramoylalanine-D-glutamate ligase for use as tool in identifying modulators which prevent microbial infection; bactericides
09/29/2005US20050214772 Thio modified aptamer synthetic methods and compositions
09/29/2005US20050214768 Regulation of human serine/threonine kinase
09/29/2005US20050214762 Receptor binding domains of leptin; proteolysis; fusion proteins
09/29/2005US20050214755 Map kinase integrin-binding domain
09/29/2005US20050214376 Hydrogel-containing medical articles and methods of using and making the same
09/29/2005US20050214374 Artificial extracellular matrix and process for producing the same
09/29/2005US20050214358 Fatty acid binding proteins; synthetic milk; for promoting mammalian pheromone receptor expression
09/29/2005US20050214356 Self assembling activation agents targeted using active drug release
09/29/2005US20050214346 For reducing serum cholesterol by increasing high density lipoprotein concentration; hypercholesterolemia
09/29/2005US20050214341 Three dimensional, malleable cell culture; tissue engineering; pluripotent cells
09/29/2005US20050214331 Pharmaceutical compositions for bioactive peptide agents
09/29/2005US20050214330 Process for producing sustained-release composition
09/29/2005US20050214328 Administering an immunomodulatory compound (1-oxo- or 1,3-dioxo-2-(2,6-dioxopiperidin-3yl) isoindolines); inhibiting cell growth or proliferation, removing or improving acne scar, or reducing or correcting wrinkle line; senile keratosis
09/29/2005US20050214327 Neurotoxin-containing suppositories and related methods
09/29/2005US20050214326 Amino acid and zinc containing botulinum toxin pharmaceutical compositions
09/29/2005US20050214325 Administering a neurotoxin and a neuron growth inhibitor to treat or prevent dermatological, urological, thyroid, optical, and neurological conditions; dystonia, hyperthyroidism, hypothyroidism, Graves' disease, goiter, thyroiditis, cancer, migraine, chronic pain, fibromyalgia, stroke, brain injury
09/29/2005US20050214321 Recombinant icosahedral virus like particle production in pseudomonads
09/29/2005US20050214320 Mycobacterium vaccae; enhancement of immune Th1 or Th2 responses to heterologous antigens; tuberculosis, autoimmune thyroiditis, insulin-dependent diabetes mellitus, multiple sclerosis, Crohn's disease, peptic ulcers, organ transplant rejection, sarcoidosis, asthma, allergic rhinitis, cancer, lupus
09/29/2005US20050214319 Peptides and DNA encoding peptides that carry novel cytotoxic T lymphocyte epitopes derived from fragments of human immunodeficiency virus-1 Pol or envelope proteins and carry HLA-A*1101 binding motif; vaccines
09/29/2005US20050214315 Antibodies to human IL-17F and other CTLA-8-related proteins and methods related thereto
09/29/2005US20050214314 Human cytokine receptor
09/29/2005US20050214313 Extracellular domain of CTLA4, with (a) an alanine at position +29 substituted with tyrosine, leucine, tryptophan, or threonine, and (b) a leucine at position +104 substituted with glutamic acid; binds CD80 and/or CD86 with greater avidity; inhibiting graft versus host disease
09/29/2005US20050214307 Antibody conjugates for treatment of neoplastic disease
09/29/2005US20050214305 VEGI, an inhibitor of angiogenesis and tumor growth
09/29/2005US20050214300 Methods for treating cancer using Porimin as a target
09/29/2005US20050214296 Methods of modulating cytokine activity; related reagents
09/29/2005US20050214295 Combined chemotherapy compositions and methods for the treatment of cancer, ischemia-reperfusion injury, and septic shock
09/29/2005US20050214294 Diabetic nephropathy therapies
09/29/2005US20050214293 Containing heavy and light chain complementarity determining region 1,2 and 3 components of amino acid sequences 1-6; reduced immunogenicity; increased affinity and avidity; improved cell culturing
09/29/2005US20050214291 Treatment method
09/29/2005US20050214290 Methods of blocking tissue destruction by autoreactive T cells
09/29/2005US20050214287 Methods and compositions for modulating angiogenesis
09/29/2005US20050214281 G-protein coupled receptor
09/29/2005US20050214276 Delta 4, 5 glycuronidase and uses thereof
09/29/2005US20050214275 Noninvasive fat modulation; utilizing active agents having reactive selectivity to metabolic regulatory system of cells; drug screening; animal models
09/29/2005US20050214262 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine
09/29/2005US20050214260 Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
09/29/2005US20050214257 Using self assembling peptide amphiphiles in organ or tissue transplant materials
09/29/2005US20050214255 N-acylated chitinous polymers and methods of use thereof
09/29/2005US20050214253 Interferon-beta fusion proteins and uses
09/29/2005US20050214252 Chordin-like molecules and uses thereof
09/29/2005US20050214251 Stability and rapid onset of action; may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration
09/29/2005US20050214242 Compositions containing internally activated antioxidant
09/29/2005US20050214213 Cone snail peptides
09/29/2005DE102004011663A1 Erythropoietin-Flüssigformulierung Erythropoietin liquid formulation
09/29/2005CA2843966A1 Follicle stimulating hormone superagonists
09/29/2005CA2560636A1 Glycosylation variants of ricin-like proteins
09/29/2005CA2560525A1 Immunosuppressive cytokine
09/29/2005CA2560269A1 Combinatorial methods and compositions for treatment of melanoma
09/29/2005CA2560261A1 Method for the delivery of sustained release agents
09/29/2005CA2560259A1 Methods for increasing protein polyethylene glycol (peg) conjugation
09/29/2005CA2560247A1 Thrombin derivative and pharmaceutical composition containing the same
09/29/2005CA2560174A1 Y4 selective receptor agonists for therapeutic interventions
09/29/2005CA2560166A1 Y2/y4 selective receptor agonists for therapeutic interventions
09/29/2005CA2559936A1 Methods and compositions for using alveolar macrophage phospholipase a2
09/29/2005CA2559838A1 Y2 selective receptor agonists for therapeutic interventions
09/29/2005CA2559662A1 Novel antibiotic alternatives
09/29/2005CA2559544A1 C20orf23 as modifier of the igfr pathway and methods of use
09/29/2005CA2559543A1 Pdes as modifiers of the igfr pathway and methods of use
09/29/2005CA2559436A1 Materials for treating vascular leakage in the eye
09/29/2005CA2559280A1 Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
09/29/2005CA2559215A1 Peptides derived from human bplp protein, polynucleotides coding for said peptides and antibodies directed against said peptides
09/29/2005CA2559211A1 Detection, isolation and uses of renalase (monoamine oxidase c)
09/29/2005CA2559127A1 Methods and compositions for the treatment of conditions related to gastric acid secretion
09/29/2005CA2558583A1 Polymer-based compositions and conjugates of hiv entry inhibitors
09/29/2005CA2558371A1 Methods of modulating immune responses by modulating tim-1 and tim-4 function
09/29/2005CA2557174A1 Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing same
09/29/2005CA2556917A1 Process for preparing macrocyclic compounds
09/29/2005CA2555363A1 Coenzyme q compositions persisting in blood
09/29/2005CA2555036A1 Antithrombotic compound
09/29/2005CA2554018A1 Lyophilization method to improve excipient crystallization
09/29/2005CA2522609A1 Methods and systems for treatment of neurological diseases of the central nervous system
09/28/2005EP1580272A2 TAT transdominant variants of human immunodeficiency virus (HIV)
09/28/2005EP1580266A1 Screening method
09/28/2005EP1579871A1 Vascular endothelial cell growth factor antagonists and uses thereof
09/28/2005EP1579868A2 Use of IL-11 for treating various diseases
09/28/2005EP1579867A1 Medicinal composition for treating ischemic cardiac failure
09/28/2005EP1579866A1 Novel use of edg receptors
09/28/2005EP1579865A1 Means for preventing and curing endocrine system disturbances
09/28/2005EP1579863A2 Combination therapy with anti-gastrin G17 antibodies for the treatment of tumors
09/28/2005EP1579860A1 Bone regeneration product for human and veterinary use, containing melatonin as active principle
09/28/2005EP1579855A1 Novel dry powder inhalation system for transpulmonary administration
09/28/2005EP1579221A2 Uses of hmgb, hmgn, hmga proteins
09/28/2005EP1579218A2 Method of modulation of interaction between receptor and ligand
09/28/2005EP1579010A2 Susceptibility gene for myocardial infarction; methods of treatment
09/28/2005EP1579006A2 Modulation of jagged 1 expression
09/28/2005EP1579001A2 Materials and methods for prevention and treatment of rna viral diseases
09/28/2005EP1578996A2 Compositions and methods for the diagnosis and treatment of tumor
09/28/2005EP1578993A2 METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IgE SYNTHESIS UTILIZING A B-CELL ASSOCIATED PROTEIN
09/28/2005EP1578991A2 Methods of diagnosing & treating diabetes and insulin resistance
09/28/2005EP1578989A2 Novel nucleic acids and secreted polypeptides
09/28/2005EP1578988A2 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
1 ... 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 ... 3163